Kelsee (Dienogest, Ethinylestradiol | Lactose)

Dienogest is a progestogenic component that suppresses the luteinizing hormone surge, thereby preventing ovulation. It also thickens cervical mucus and induces endometrial changes, which together reduce the likelihood of fertilization and implantation when combined with the estrogen component.

The prescriber determines the dosing schedule for Kelsee. Typically, it is taken as one tablet daily at the same time for 21 consecutive days followed by a pill‑free interval, but the exact regimen must be set by a qualified healthcare professional.

Kelsee is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can cause fetal harm. Limited data exist for breastfeeding; generally, combined oral contraceptives are not recommended while nursing without medical advice.

To order Kelsee, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any required import documentation.

Kelsee contains a low‑dose progestogen (dienogest) and a standard estrogen dose (ethinylestradiol), offering effective contraception with a potentially lower impact on lipid profiles compared with some older formulations. Its side‑effect profile is similar to other COCs, but individual tolerance may vary, making it a suitable alternative for patients seeking a newer progestogen.

Kelsee tablets should be stored at room temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and ensure they are out of reach of children.

Kelsee is taken orally with a glass of water, preferably at the same time each day. Consistent daily intake helps maintain hormone levels and maximizes contraceptive effectiveness.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), severe hypertension, and rare hepatic adenomas. Patients should be monitored for signs of clotting, sudden headache, visual changes, or unexplained abdominal pain.

Kelsee is contraindicated in women who are pregnant or planning pregnancy, have a history of thromboembolic disorders, are smokers over 35 years of age, have uncontrolled hypertension, active liver disease, or estrogen‑dependent tumors such as certain breast cancers.